Lynn Shapiro Snyder, a Senior Member of the Firm in the Health Care and Life Sciences and Litigation practices, in the firm’s Washington, DC, office, presents “Health Insurance Exchanges: Examining Potential Impact on Market Access Strategy.”
The Affordable Care Act has been a source of contention for the past several years, as manufacturers struggle to accurately predict the effects of state-run health insurance exchanges on a product’s market access plan. As each state will have the power to decide which insurers can participate and also set additional quality and pricing guidelines than that of the federally-run exchange, reimbursement and market access executives are concerned that if limited participation is implemented this may negatively affect a patient’s ability to access a particular drug. On the other hand, pharmaceutical companies should experience an increase in profit margins as millions of new consumers will become insured and medications will become more affordable for many patients.
- Differences in state-run, state-federal partnership vs federally-run exchanges
- Trends in state-run exchanges: limiting insurer participation
- Implications for market access and pricing of pharmaceuticals
For more inforrmation, click here.